San Diego biotech AnaptysBio has hired a chief financial officer and signaled to the U.S. Securities and Exchange Commission that it plans to go public.

The company has not priced its initial public offering, but filed an S-1 registration statement with the SEC on Dec. 28 stating its plans to sell shares of its common stock.

The firm, which employs about 50 people in San Diego, is developing antibody product candidates to treat inflammation.

AnaptysBio announced Tuesday that it had brought on Dominic Piscitelli as chief financial officer to oversee the company’s accounting and reporting functions. Piscitelli previously was at biopharmaceutical company Medivation Inc., where he played a key role in Pfizer Inc.’s $14 billion acquisition of the company, according to AnaptysBio. He also served at Astellas Pharmaceuticals and OSI Pharmaceuticals.